Chesapeake Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.89M Sell
3,142
-161
-5% -$163K 0.89% 32
2025
Q4
$3.55M Buy
3,303
+143
+5% +$137K 1.06% 26
2025
Q3
$2.41M Buy
3,160
+65
+2% +$48.4K 0.74% 41
2025
Q2
$2.41M Sell
3,095
-45
-1% -$35K 0.8% 40
2025
Q1
$2.59M Sell
3,140
-113
-3% -$94K 0.93% 32
2024
Q4
$2.51M Sell
3,253
-177
-5% -$147K 0.86% 37
2024
Q3
$3.04M Sell
3,430
-107
-3% -$96.2K 1.04% 27
2024
Q2
$3.2M Sell
3,537
-135
-4% -$108K 1.16% 23
2024
Q1
$2.86M Sell
3,672
-509
-12% -$362K 1.04% 30
2023
Q4
$2.44M Sell
4,181
-236
-5% -$138K 0.94% 33
2023
Q3
$2.37M Sell
4,417
-283
-6% -$146K 0.99% 29
2023
Q2
$2.2M Sell
4,700
-59
-1% -$24.7K 0.87% 37
2023
Q1
$1.63M Sell
4,759
-79
-2% -$26.6K 0.68% 46
2022
Q4
$1.77M Sell
4,838
-198
-4% -$70.2K 0.78% 38
2022
Q3
$1.63M Sell
5,036
-258
-5% -$81.7K 0.74% 37
2022
Q2
$1.72M Sell
5,294
-66
-1% -$19.8K 0.73% 38
2022
Q1
$1.53M Sell
5,360
-333
-6% -$85.7K 0.56% 45
2021
Q4
$1.57M Sell
5,693
-180
-3% -$45.6K 0.53% 49
2021
Q3
$1.36M Sell
5,873
-685
-10% -$169K 0.49% 55
2021
Q2
$1.51M Sell
6,558
-743
-10% -$149K 0.49% 51
2021
Q1
$1.36M Sell
7,301
-385
-5% -$75.3K 0.46% 59
2020
Q4
$1.3M Sell
7,686
-329
-4% -$49.1K 0.44% 65
2020
Q3
$1.19M Sell
8,015
-5
-0.1% -$774 0.44% 67
2020
Q2
$1.32M Buy
8,020
+58
+0.7% +$8.9K 0.52% 53
2020
Q1
$1.1M Sell
7,962
-17
-0.2% -$2.34K 0.51% 57
2019
Q4
$1.05M Sell
7,979
-2,164
-21% -$251K 0.4% 78
2019
Q3
$1.13M Sell
10,143
-6,512
-39% -$725K 0.46% 68
2019
Q2
$1.84M Buy
16,655
+1,935
+13% +$228K 0.77% 31
2019
Q1
$1.91M Buy
14,720
+3,297
+29% +$401K 0.84% 23
2018
Q4
$1.32M Buy
11,423
+2,510
+28% +$280K 0.65% 38
2018
Q3
$957K Sell
8,913
-149
-2% -$14.9K 0.43% 65
2018
Q2
$774K Sell
9,062
-381
-4% -$31.3K 0.36% 76
2018
Q1
$730K Buy
+9,443
New +$760K 0.34% 81

Other funds holding LLY

Chesapeake Wealth Management's LLY Position: Q1 2026 in Review

Chesapeake Wealth Management reduced its Eli Lilly (LLY) stake by 4.9% in Q1 2026, selling an estimated $163K and leaving 3,142 shares worth $2.89M. The position accounts for 0.89% of the portfolio, ranked #32.

Chesapeake Wealth Management first reported a position in LLY in Q1 2018 and has held it in 33 quarters since. The position peaked at $3.55M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Chesapeake Wealth Management held 3,142 shares of Eli Lilly worth $2.89M as of Q1 2026.
  • Chesapeake Wealth Management sold 161 Eli Lilly shares in Q1 2026, an estimated $163K.
  • Eli Lilly made up 0.89% of Chesapeake Wealth Management's portfolio in Q1 2026, its #32 holding.
  • Chesapeake Wealth Management first reported a position in Eli Lilly in Q1 2018 and has held it in 33 quarters since.
  • Chesapeake Wealth Management's Eli Lilly position peaked at $3.55M in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Chesapeake Wealth Management's 13F filing for Q1 2026, filed 18 May 2026.